Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians
DOI: 10.1055/s-0043-1774410
Letter to the Editor

Unveiling the Eris Subvariant: The Next Challenge in the COVID-19 Pandemic?

Arunava Kali
1   Department of Microbiology, Mahatma Gandhi Medical College and Research Institute, Pondicherry, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Since the COVID-19 pandemic's onset, the SARS-CoV-2 virus has displayed remarkable mutation abilities, resulting in distinct variants. Alpha, Beta, Gamma, Delta, and Omicron are major World Health Organization (WHO)-identified variants of concern. The Omicron variant and its sub-lineages dominated globally in 2022. A novel strain, EG.5.1 (Eris), originating from Omicron's XBB sub-lineage, has recently sparked a significant COVID-19 surge across continents. Detected since June 2023, EG.5.1 is linked to increased cases in Europe, the Americas, and Asia. Factors like waning immunity, overcrowding, and poor air quality contributed to its rise. This variant is likely to prevail over other circulating variants and become dominant in UK by September 2023. Surveillance of its global epidemiology and implementing preventive measures have become imperative in light of the current situation.

Keywords

EG.5.1 - Eris subvariant - SARS-CoV-2

Presentation at a Meeting

None.




Publication History

Received: 07 August 2023

Accepted: 12 August 2023

Article published online:
08 September 2023

© 2023. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India